Transparency data

Non-tech summaries 2016: projects on cardiovascular disorders

Projects granted during 2016 that have a primary purpose of translational applied research - human cardiovascular disorders.


Non-technical summaries: projects granted in 2016, volume 18

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research - human cardiovascular disorders.

The following projects were granted:

  • analysing signalling gene function in the heart (heart, electrophysiology, hypertrophy, arrhythmias)

  • mechanisms of innate immunity in cardiovascular disease (heart disease, immune system)

  • prevention of chronic heart failure (heart failure, myocardial infarction, diabetes, hypercholesterinaemia)

  • genetic and bioenergetic determinants of cardiac arrhythmias (arrhythmias, heart disease, sudden death, genetics)

  • autonomic control of the cardiovascular system (cardiovascular disease, autonomic control)

  • the effects of myocardial infarction (myocardial infarction)

  • preclinical therapies for pulmonary hypertension (cardiovascular, pulmonary, genetics, therapy)

  • pathophysiology of the cardiovascular system (metabolic syndrome; obesity; heart function; atherosclerosis)

  • comparative cardiovascular homeostasis (transgenics; hypertension; metabolism; kidney)

  • mechanisms of progressive cardiac dysfunction (heart failure, hypertrophy, cardiac remodelling)

  • pathophysiology of heart failure (heart failure, calcium, β-adrenergic, ultrastructure)

  • cardiac injury, repair, regeneration & remodelling (heart attack, drug therapy, heart failure)

  • dietary vascular protection in utero and stroke (stroke, obesity, pregnancy, risk, diabetes)

  • mechanisms of thrombosis and atherosclerosis (macrophages, endothelial cells, inflammation, atherosclerosis, thrombosis, cardiovascular disease)

  • investigating the genetics of cardiovascular disease (hypertension, organ-damage, rats, mice, genetics)

  • investigating a novel treatment for heart failure (perhexiline, metabolism, hypertrophy, heart failure)

  • small animal models of cardiovascular disease (ischaemia, therapy, cardiovascular disease)

  • regulation of thrombosis and haemostasis and its influence on cardiovascular diseases (clot, thrombosis, stroke, atherosclerosis, vessel wall)

  • pathogenesis and therapy of vascular diseases (atherosclerosis; aneurysm; angiogenesis; cell therapy; cardiovascular diseases intervention.)

  • rodent models of arteriosclerosis (arteriosclerosis, stem cells, endothelial cells, vessel graft)

  • role of nitric oxide and reactive oxygen species in cardiac function (nitric oxide, reactive oxygen species, heart failure, diabetes, atrial fibrillation)

  • rodent models of pulmonary hypertension and associated co-morbidities (pulmonary hypertension, pulmonary vascular remodelling, right heart failure)

  • vascular protective genes in angiogenesis (vascular, preeclampsia, hydrogen sulphide, heme oxygenase, pregnancy)

  • myocardial infarction and heart failure (heart, failure, infarction, protection, injury)

  • angiogenesis, microcirculation and microenvironment (angiogenesis, microcirculation, tumour growth, wound-healing, vascular-targeted)

  • protecting and repairing the diseased heart (heart attack, cardiac surgery, ischemia reperfusion injury)

  • factors affecting valve development and disease (veins, lymphatics, heart)

  • studies of complex genetic traits in rats (rat, cardiovascular, metabolic, kidney genetics)

  • mechanistic studies in pre-clinical stroke/small vessel disease (stroke, small vessel disease, hypertension, rats, mice)

  • understanding and treating cardiovascular disease (cardiovascular development, heart repair)

  • the molecular basis of cardio-metabolic disease (diabetes, cardiovascular disease, insulin resistance, insulin-like growth factors, atherosclerosis)

  • myocardial infarction (heart attack, vascular dysfunction, nitrite, nitric oxide, perhexiline)

  • calcium-permeable channels and their associated mechanisms and therapeutic potential (blood vessel, cardiovascular disease, cancer, diabetes, calcium channels)

  • improving minimally invasive treatment of coronary artery disease (coronary, artery, atherosclerosis, angioplasty, stents)

  • targeting the immune response in cardiovascular diseases (atherosclerosis; restenosis; aneurysm; myocardial infarction; stroke)

  • innovative treatments for heart failure (heart failure, stem cell therapy, gene therapy, drug therapy)

  • ischaemia-reperfusion injury and shock (ischaemia, shock, kidney, haemorrhage, heart research, trauma)

  • the long-term effects of prenatal hypoxia on cardiomyocyte function (programming, pre-natal hypoxia, cardiac, mitochondria, myocyte)

Published 21 December 2017